UNIQURE NV (QURE) Stock News

NASDAQ:QURE - NL0010696654 - Common Stock

15.7 USD

+0.15 (+0.96%)

Last: 8/22/2025, 8:00:02 PM

15.7 USD

0 (0%)

After Hours: 8/22/2025, 8:00:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

QURE Latest News, Press Relases and Analysis

All

Press Releases

12 days ago - By: Benzinga - Mentions: NVAX SRPT MRNA CABA ...

Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction

24 days ago - By: Benzinga - Mentions: SRPT CAPR NTLA RCKT ...

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

25 days ago - By: The Motley Fool

uniQure Narrows Loss in Fiscal Q2

25 days ago - By: uniQure Inc.

uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

25 days ago - By: uniQure Inc.

uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

a month ago - By: uniQure Inc.

uniQure to Announce Second Quarter 2025 Financial Results

a month ago - By: uniQure Inc.

uniQure to Announce Second Quarter 2025 Financial Results

2 months ago - By: uniQure Inc.

uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer

2 months ago - By: uniQure Inc.

uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer

3 months ago - By: Yahoo Finance - Mentions: CLPT

Lake Street says AMT-130 could be ‘significantly impactful’ for ClearPoint

3 months ago - By: uniQure Inc.

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

3 months ago - By: uniQure Inc.

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

3 months ago - By: uniQure Inc.

uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)

3 months ago - By: uniQure Inc.

uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)

3 months ago - By: Zacks Investment Research - Mentions: ILMN BEAM NTLA CRSP ...

3 Top Genomics Stocks to Add to Your Portfolio in 2025

3 months ago - By: Zacks Investment Research

Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?

4 months ago - By: Zacks Investment Research - Mentions: SPRO

UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

4 months ago - By: uniQure Inc.

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

4 months ago - By: uniQure Inc.

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

4 months ago - By: uniQure Inc.

uniQure to Announce First Quarter 2025 Financial Results

4 months ago - By: uniQure Inc.

uniQure to Announce First Quarter 2025 Financial Results

4 months ago - By: Investor's Business Daily - Mentions: SIRI RY RY.CA SRPT ...

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost

4 months ago - By: uniQure Inc.

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease

4 months ago - By: uniQure Inc.

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease